safety and immunogenicity
Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules
... The study also has significant strengths. State-of-the art laboratory techniques were used to evaluate immunogenicity, and the study followed every participant until the age of 1 year for safety outcomes. ...
12
Safety and Immunogenicity of Heptavalent Pneumococcal Vaccine Conjugated to CRM
... be safety limitations and/or immuno- logic limitations on the number of serotypes of po- lysaccharide-protein conjugated vaccine that can be combined into a single dose of ...decreased immunogenicity, or in ...
10
Safety and Immunogenicity of a Recombinant Influenza Vaccine: A Randomized Trial
... noninferior immunogenicity in adults 18 to 49 years of ...The safety and immunogenicity of the RIV3 in comparison with the IIV3 in 159 influenza vaccine-naive pediatric subjects 6 to 59 months of age ...
10
SAFETY AND IMMUNOGENICITY OF SEASONAL TRIVALENT INACTIVATED INFLUENZA VACCINES IN PREGNANT WOMEN
... of safety, immunogenicity, and efficacy of influenza vaccination for pregnant women To evaluate the effectiveness of influenza vaccination during pregnancy, it is essential to investigate whether ...
18
Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers
... Both MenACWY-CRM and MenACWY-TT protect against IMD caused by serogroups A, C, W, and Y. However, due to differ- ences in polysaccharide chain length, conjugation chemistry for protein −polysaccharide coupling, and ...
8
Descriptive Review of Safety, Reactogenicity and Immunogenicity of Dengue Vaccine Clinical Trials, 2003 – 2013
... Different regions are endemic for various flaviviruses (FV) such as yellow fever (YF) or Japanese encephaltitis (JE), which may co-exist with the dengue viruses. We note from these studies the impact of pre-existing FV ...
9
Safety and immunogenicity of plant-produced African horse sickness virus-like particles in horses
... the safety and immunogenicity of this VLP candidate vaccine in horses, and to consider ways in which the pro- duction platform could be scaled up in a cost-effective ...
6
Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial
... Vaxart has now constructed a gene-based vaccine aimed at inducing protective immunity and pre- venting norovirus illness using the same platform investigated in the influenza trials. This vaccine is expected to express ...
13
Emerging patient safety issues under health care reform: follow-on biologics and immunogenicity
... patient safety issues is difficult. In cases of immunogenicity and biologic drugs, limited scientific knowledge as to predictability, rare potential occurrence, but severe negative consequences if an ...
5
Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine
... the immunogenicity findings in the study strongly suggest that PCV13 will be comparable to PCV7 in providing protection against pneu- mococcal disease caused by the 7 common serotypes and should also af- ford ...
12
Safety and Immunogenicity of an Acellular Pertussis Vaccine in Premature Infants
... 10 In studies with whole cell pertussis vaccine, side effects of immunization of preterm infants were as high as in term infants 6 – 8 and no neurologic complications were demonstrated..[r] ...
6
Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.
... study, immunogenicity, as measured by enzyme-linked immunosorbant assay and/or ex vivo interferon (IFN)–␥ enzyme-linked immunospot assay, was documented in ...
9
Safety and immunogenicity of the DTP/HB /Hib combination vaccine: phase I study
... DQWHURODWHUDO WKLJK UHJLRQ XVLQJ D JDXJH QHHGOH RI PP OHQJWK6XEMHFWVZHUHIROORZHGIRUPRQWKDIWHUDGPLQLVWUDWLRQRI each vaccine dose to evaluate its safety, while serum anti-diphteria, ...
6
Safety and immunogenicity of a Pseudomonas aeruginosa O polysaccharide toxin A conjugate vaccine in humans
... Mice (female, NMRI strain, weighing 18-20 g) each received 200 Mg of conjugate protein, equal to 1,000 mean lethal doses of native toxin A.. Mice were observed daily for 14 d postinjecti[r] ...
7
Impact of ETIF Deletion on Safety and Immunogenicity of Equine Herpesvirus Type 1-Vectored Vaccines
... EHV-1’s safety profiles combined with its potential to in- duce transgene-specific cellular, humoral, and mucosal im- mune responses recommend this animal herpesvirus as a potent and promising new candidate for ...
12
Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
... Although the number and incidence of some of the solic- ited local reactions in the Sub/MF59™ vaccine group was greater than in the Subunit group, they were generally mild or moderate and of short duration, and no ...
8
Measles Vaccination in HIV-Infected Children: Systematic Review and Meta-Analysis of Safety and Immunogenicity
... of measles vaccine can be given as early as 6 months in areas where there is a high incidence of both measles and HIV in- fection [7]. This recommendation means that HIV infection status does not have to be known before ...
15
Evaluation of the Safety and Immunogenicity of a Candidate Tuberculosis Vaccine, MVA85A, Delivered by Aerosol to the Lungs of Macaques
... the immunogenicity of a leading candidate tuberculosis (TB) vaccine, modified vaccinia virus Ankara ex- pressing antigen 85A (MVA85A), in rhesus macaques, delivered either as an aerosol or as an intradermal boost ...
10
Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer
... The iMATRIX-atezolizumab study (NCT02541604) was a phase I/II, multicenter, open-label study to assess the safety and PK of atezolizumab in pediatric patients and young adults. The study enrolled patients with ...
13
Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine
... and immunogenicity of YF/DEN chimeras compared to those of their parent viruses (WT DEN and YF 17D) after primary immuniza- tion, (ii) whether a second dose of the tetravalent vaccine would increase the ...
15